Evidence map›Paper›PMID 33062604›Full record

ArticleAdvanced pharmaceutical bulletin2020

Transcriptome Changes in Colorectal Cancer Cells upon Treatment with Avicequinone B.

Yanet Ocampo, Daneiva Caro, David Rivera, Jhoan Piermattey, Ricardo Gaitán, Luis A Franco

Abstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanet OcampoBiological Evaluation of Promising Substances Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.ORCID https://orcid.org/0000-0003-2001-3848
Daneiva CaroBiological Evaluation of Promising Substances Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.ORCID https://orcid.org/0000-0001-8079-5664
David RiveraBiological Evaluation of Promising Substances Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.
Jhoan PiermatteyNatural Products Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.
Ricardo GaitánNatural Products Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.
Luis A FrancoBiological Evaluation of Promising Substances Group, Department of Pharmaceutical Sciences, University of Cartagena, Carrera 50 No. 29-11, 130014, Cartagena, Colombia.ORCID https://orcid.org/0000-0003-2983-0836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Avicequinone BColorectal cancerFerroptosisInterferon stimulated genesmiR-21RNA-sequencing

Identifiers

PMID33062604
PMCPMC7539315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.